Skuldtech secures funds for Alzheimer's research

Skuldtech, a genomic biomarker company has secured 1 million euros ($1.3 million) in funding from Bpifrance as part of a project on Alzheimer's disease that has received funding of 8.6 million euros in total. The program is planned to last for four years, with the first results expected in 2018.

North AmericaUSBriefs